Correlation Between Oncopeptides and Atlas Copco

Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Atlas Copco at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Atlas Copco into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncopeptides AB and Atlas Copco AB, you can compare the effects of market volatilities on Oncopeptides and Atlas Copco and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Atlas Copco. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Atlas Copco.

Diversification Opportunities for Oncopeptides and Atlas Copco

-0.69

Correlation Coefficient

Oncopeptides  Atlas Copco

Excellent diversification

The 3 months correlation between Oncopeptides and Atlas is -0.69. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Atlas Copco AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Atlas Copco AB and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Atlas Copco. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Atlas Copco AB has no effect on the direction of Oncopeptides i.e., Oncopeptides and Atlas Copco go up and down completely randomly.

Pair Corralation between Oncopeptides and Atlas Copco

Assuming the 90 days trading horizon Oncopeptides AB is expected to under-perform the Atlas Copco. In addition to that, Oncopeptides is 5.58 times more volatile than Atlas Copco AB. It trades about -0.08 of its total potential returns per unit of risk. Atlas Copco AB is currently generating about 0.15 per unit of volatility. If you would invest  13,729  in Atlas Copco AB on February 28, 2024 and sell it today you would earn a total of  3,856  from holding Atlas Copco AB or generate 28.09% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Oncopeptides AB  vs.  Atlas Copco AB

Oncopeptides AB

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in June 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Atlas Copco AB

Risk-Adjusted Performance

11 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Atlas Copco AB are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Atlas Copco sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Oncopeptides and Atlas Copco

The main advantage of trading using opposite Oncopeptides and Atlas Copco positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Atlas Copco can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atlas Copco will offset losses from the drop in Atlas Copco's long position.

The idea behind Oncopeptides AB and Atlas Copco AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.